These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 21536094)

  • 21. Clinical trials in neuroprotection.
    Whitcup SM
    Prog Brain Res; 2008; 173():323-35. PubMed ID: 18929119
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Clinical pharmacology and therapeutic aspects in certain degenerative neurological diseases].
    Maloteaux JM
    Bull Mem Acad R Med Belg; 1996; 151(10-11):429-32; discussion 432-4. PubMed ID: 9491620
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Neuroprotective and neurotoxic roles of levodopa (L-DOPA) in neurodegenerative disorders relating to Parkinson's disease.
    Kostrzewa RM; Kostrzewa JP; Brus R
    Amino Acids; 2002; 23(1-3):57-63. PubMed ID: 12373519
    [TBL] [Abstract][Full Text] [Related]  

  • 24. An overview of investigational antiapoptotic drugs with potential application for the treatment of neurodegenerative disorders.
    Camins A; Sureda FX; Junyent F; Verdaguer E; Folch J; Beas-Zarate C; Pallas M
    Expert Opin Investig Drugs; 2010 May; 19(5):587-604. PubMed ID: 20402598
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Flavopiridol: an antitumor drug with potential application in the treatment of neurodegenerative diseases.
    Pallàs M; Verdaguer E; Jordà EG; Jiménez A; Canudas AM; Camins A
    Med Hypotheses; 2005; 64(1):120-3. PubMed ID: 15533627
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Challenges and opportunities in CNS delivery of therapeutics for neurodegenerative diseases.
    Barchet TM; Amiji MM
    Expert Opin Drug Deliv; 2009 Mar; 6(3):211-25. PubMed ID: 19290842
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Neuroprotection in progressive brain disorders.
    Djaldetti R; Lev N; Melamed E
    Isr Med Assoc J; 2003 Aug; 5(8):576-80. PubMed ID: 12929297
    [TBL] [Abstract][Full Text] [Related]  

  • 28. List of drugs in development for neurodegenerative diseases. Update September 2005.
    Kwon MO; Herrling P
    Neurodegener Dis; 2005; 2(2):61-108. PubMed ID: 16909049
    [No Abstract]   [Full Text] [Related]  

  • 29. Oxidative stress, mitochondrial dysfunction and cellular stress response in Friedreich's ataxia.
    Calabrese V; Lodi R; Tonon C; D'Agata V; Sapienza M; Scapagnini G; Mangiameli A; Pennisi G; Stella AM; Butterfield DA
    J Neurol Sci; 2005 Jun; 233(1-2):145-62. PubMed ID: 15896810
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Finding order within disorder: elucidating the structure of proteins associated with neurodegenerative disease.
    Huang A; Stultz CM
    Future Med Chem; 2009 Jun; 1(3):467-82. PubMed ID: 21426127
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Disease-modifying drugs and Parkinson's disease.
    Allain H; Bentué-Ferrer D; Akwa Y
    Prog Neurobiol; 2008 Jan; 84(1):25-39. PubMed ID: 18037225
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Neuroimmunophilins: a novel drug therapy for the reversal of neurodegenerative disease?
    Poulter MO; Payne KB; Steiner JP
    Neuroscience; 2004; 128(1):1-6. PubMed ID: 15450348
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Multi-Target Directed Drugs as a Modern Approach for Drug Design Towards Alzheimer's Disease: An Update.
    de Freitas Silva M; Dias KST; Gontijo VS; Ortiz CJC; Viegas C
    Curr Med Chem; 2018; 25(29):3491-3525. PubMed ID: 29332563
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Molecular Hybridization as a Tool in the Design of Multi-target Directed Drug Candidates for Neurodegenerative Diseases.
    Gontijo VS; Viegas FPD; Ortiz CJC; de Freitas Silva M; Damasio CM; Rosa MC; Campos TG; Couto DS; Tranches Dias KS; Viegas C
    Curr Neuropharmacol; 2020; 18(5):348-407. PubMed ID: 31631821
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The role of natural products in the discovery of new drug candidates for the treatment of neurodegenerative disorders I: Parkinson's disease.
    Campos HC; da Rocha MD; Viegas FP; Nicastro PC; Fossaluzza PC; Fraga CA; Barreiro EJ; Viegas C
    CNS Neurol Disord Drug Targets; 2011 Mar; 10(2):239-50. PubMed ID: 20874702
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Melatonin as a versatile molecule to design novel multitarget hybrids against neurodegeneration.
    Ramos E; Egea J; de Los Ríos C; Marco-Contelles J; Romero A
    Future Med Chem; 2017 May; 9(8):765-780. PubMed ID: 28498717
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Multitarget-directed ligands for neurodegenerative diseases: real opportunity or blurry mirage?
    Benchekroun M; Maramai S
    Future Med Chem; 2019 Feb; 11(4):261-263. PubMed ID: 30763133
    [No Abstract]   [Full Text] [Related]  

  • 38. Davunetide: a review of safety and efficacy data with a focus on neurodegenerative diseases.
    Morimoto BH; Fox AW; Stewart AJ; Gold M
    Expert Rev Clin Pharmacol; 2013 Sep; 6(5):483-502. PubMed ID: 23971871
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Repositioning and development of new treatments for neurodegenerative diseases: Focus on neuroinflammation.
    Arbo BD; Schimith LE; Goulart Dos Santos M; Hort MA
    Eur J Pharmacol; 2022 Mar; 919():174800. PubMed ID: 35131314
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Investigating targets for neuropharmacological intervention by molecular dynamics simulations.
    Rossetti G; Kless A; Lai L; Outeiro TF; Carloni P
    Biochem Soc Trans; 2019 Jun; 47(3):909-918. PubMed ID: 31085614
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.